Inventure

Today we're proud to announce we've backed MONCYTE Health to enable a new era of personalized treatment strategies for high cholesterol. 1.5 billion people are at risk of strokes and heart attacks due to high cholesterol, and no treatment plan is a one-size-fits-all. Moncycte's technology can quantify individual differences in cellular lipid uptake and storage, assisting physicians to prescribe the proper treatment, and pharmaceutical companies to study how novel lipid-lowering drugs influence the cellular processes contributing to cardiovascular risk. Congratulations to Tamara, Simon, and the entire MONCYTE team!

Great session this morning with our People and Operations lead, Therese Öberg!

Proud moment as a pre-seed investor. 1 million sold policies.. 👏 cc Inventure

A great day - Canatu starts the next journey as a listed company in the Helsinki Stock Exchange. Keep on rocking !! https://lnkd.in/dm-332QN

I’ll be in NYC🗽next week and can’t wait to catch-up with old and new connections in VC and tech. Excited to finally meet in person Andy Weissman and hang out at your beautiful office Union Square Ventures. Also reconnecting with brilliant Brandon with Battery Ventures. Excited to catch-up with you Sophie with Insight Partners. And many others VCs, LPs, angels and founders 💫 really looking forward meeting you all! ➡️Who else should I catch-up with!? Dm if you want to chat about early stage investing in Europe and find synergies! 🇪🇺🤝🇺🇸

In our latest newsletter, we ran through the headlines of a busy summer: Canatu going public, Steep and toddle moving from pre-seed to seed, and a few exciting new portfolio companies including Biomatter, Valo, and Livv Health. Read all that and more, here:

Cooking up the next big thing? Catch Linus, Lauri, and Kevin this week at TechBBQ!

We’re thrilled to announce that our upcoming Finch webinar reached full capacity in less than 48 hours, with all 500 slots filled! 🙌 Jesper Wallgren, Amelia Vey Henry and I are excited to connect with so many of you. For those who couldn’t secure a spot, don’t worry—we’ve got you covered! We’ll post the registration link in the comments so you can receive the recording after the webinar.

Long overdue announcement of our investment into Biomatter ☝- together with UVC Partners we are leading Biomatter's €6.5m seed round 🤝 We are currently experiencing a seismic shift in the field of synthetic biology, supercharged by AI and rapidly advancing multiple new research and development directions - among others within protein design. 🔬 Biomatter sits at the forefront of this shift, having designed the first fully functional enzymes with generative AI globally (in 2019) and is now enabling global companies to design and build new enzymes “bottom-up”, without the traditional constraints of natural enzymes, greatly expanding the potential scope of their application. ⛓ But what really drove us was the team, having sat down many times with the team around Laurynas, Irmantas, Vykintas and Donatas, experiencing their force of nature and willingness to push the boundaries of what's possible beyond current imagination made this a no-brainer call. 💣 More on that below (also for my German friends) ⬇ (cc Oliver, Practica Capital, Donatas, Metaplanet, Lemonade Stand)

We're excited to announce our investment in Biomatter, leading their €6.5M Seed round alongside UVC Partners. There's huge potential in this technology. Biomatter is revolutionizing enzyme design with AI, creating custom designed enzymes from scratch that could transform industries from pharma to agriculture. Why are we so excited? Kevin Lösch writes that now we're not limited to tweaking the enzymes we discover in nature- the only limit is our creativity. We see this as transformative for enzyme design as CRISPR was for gene editing. Read more about why we invested in Laurynas, Irmantas, Donatas, Vykintas, and the biomatter team, and the potential impact of this game-changing technology here: